The project achieved several results beyond the current state of the art. A recombinant expression system for the TFF2 peptide was successfully developed with improved yields, enabling future functional and therapeutic studies on this previously unaccessible peptide. Stable analogues of the antimicrobial peptide CATH-2 were produced, demonstrating enhanced stability and effective antimicrobial and antibiofilm activity, addressing the common degradation and solubility limitations of native peptides.
In parallel, the development of a mesoporous silica nanoparticle formulation platform enabled efficient enhancement of solubility and targeted gastrointestinal release. This platform has strong potential for controlled delivery of other bioactive molecules and for improving the oral bioavailability of peptide therapeutics.
The results have significant commercial and clinical potential. A patent draft has been prepared on the MSN nanoformulation platform, and industrial partners have been contacted for co-development. To ensure further uptake, proof-of-concept and follow-up funding applications have been submitted.
Future work will focus on scaling up nanoparticle production, validating peptide activity in animal models, and ensuring compliance with regulatory and safety requirements for translational use. Support from the Technology Transfer Office of the University of Vienna, together with ongoing collaborations and international networking, will facilitate commercialisation, licensing, and clinical translation. Overall, the project provides new therapeutic and formulation strategies that can transform peptide drug development and have a lasting impact on European biomedical innovation.
